Providence First Trust’s AstraZeneca AZN Stock Holding History

Providence First Trust’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$583K	Buy	3,092 +246	+9%	+$46.3K	0.16%	137
2026 Q1	$561K	Buy	2,846 +1,000	+54%	+$193K	0.2%	112
2025 Q4	$339K	Buy	+1,846	New	+$324K	0.12%	141

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Providence First Trust's AZN Position: Q2 2026 in Review

Providence First Trust increased its AstraZeneca (AZN) stake by 8.6% in Q2 2026, buying an estimated $46.3K and bringing the position to 3,092 shares worth $583K. The position accounts for 0.16% of the portfolio, ranked #137.

Providence First Trust first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Providence First Trust held 3,092 shares of AstraZeneca worth $583K as of Q2 2026.
Providence First Trust bought 246 AstraZeneca shares in Q2 2026, an estimated $46.3K.
AstraZeneca made up 0.16% of Providence First Trust's portfolio in Q2 2026, its #137 holding.
Providence First Trust first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Providence First Trust's 13F filing for Q2 2026, filed 27 Jul 2026.